HonCode

Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 03-20-2005, 07:13 PM   #1
Merridith
Guest
 
Posts: n/a
This is a 6 page article:


Introduction
Can Schedule/Sequence Alterations Affect Outcomes?
Evaluating New Therapeutic Regimens in the Metastatic Setting
Future Directions in Chemotherapeutic Management
Conclusions
References

http://www.medscape.com/viewarticle/491728
  Reply With Quote
Old 03-20-2005, 08:34 PM   #2
al from canada
Guest
 
Posts: n/a
Great article Merridith.
One thing all of these articles refers to is Response Rate, Time to Disease Progression (TTP), and Overall Survival (OS). My question is: many of these novel therapies or novel combinations have a significantly different TTP but have a non-significant OS. In otherwords, why is it if we can stall the TTP you still died just as early as the lower TTP study arm? Is this a statistical anomoly or a medical fact?
Al
  Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 01:51 PM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2018, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007
free webpage hit counter